Enveric Biosciences reports Q3 2023 net loss of $2.82M; cash $4.27M; advances psychedelic pipeline

Enveric Biosciences, Inc.

2023-Q3 EPS reported -$6.62

Net loss of $2.82M ($1.30 per share) vs $2.60M ($1.46 per share) in Q3 2022.
Cash and cash equivalents of $4.27M as of Sept 30, 2023.
Granted two US patents for EVM301 Series and EB-373; filed six non-US applications.
Completed manufacturing of EB-373; preclinical data show oral bioavailability and safety.
AI drug discovery engine Psybrary surpassed 1,000 compounds analyzed.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Enveric Biosciences, Inc. reported financial results for the third quarter ended September 30, 2023.

Period: the third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 13, 2023, Enveric Biosciences, Inc. issued a press release providing a corporate update and announcing its financial results for the third quarter ended September 30, 2023.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Enveric Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-040499

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.